Journal of Neuroscience · 2019 · 22 citations · 43 references
Life SciencesNeurobiologyNeuroscienceMolecular NeuroscienceNeurogeneticsPharmacogeneticsAddictionDrug DependenceNeurotransmissionReceptor PolymorphismsReward PathwaysSynaptic TransmissionAddiction LiabilityAddiction VulnerabilityDopaminergic NeuronsGenetic Vulnerability To AddictionGenetics Of Opioid AddictionOpioid PharmacogeneticsOpioid Receptor PolymorphismsOpioid Reward System
Mu-opioid receptors (MORs) are the primary site of action of opioid drugs, both licit and illicit. Susceptibility to opioid addiction is associated with variants in the gene encoding the MOR, <i>OPRM1</i>. Varying with ethnicity, ∼25% of humans carry a single nucleotide polymorphism (SNP) in <i>OPRM1</i> (A118G). This SNP produces a nonsynonymous amino acid substitution, replacing asparagine (N40) with aspartate (D40), and has been linked with an increased risk for drug addiction. While a murine model of human <i>OPRM1</i> A118G (A112G in mouse) recapitulates most of the phenotypes reported in humans, the neuronal mechanisms underlying these phenotypes remain elusive. Here, we investigated the impact of A118G on opioid regulation of synaptic transmission in mesolimbic VTA dopaminergic neurons. Using electrophysiology, we showed that both inhibitory and excitatory inputs to VTA dopaminergic neurons projecting to the NAc medial shell were suppressed by the MOR agonists DAMGO and morphine, which caused a shift in the excitatory/inhibitory balance and an increased action potential firing rate. Mice carrying the 112G/G allele exhibited lower sensitivity to DAMGO and morphine compared with major allele carriers (112A/A). Paradoxically, DAMGO produced facilitatory effects on mEPSCs, which were mediated by presynaptic GABA<sub>B</sub> receptors. However, this was only prominent in homozygous major allele carriers, which could explain a stronger shift in action potential firing in 112A/A mice. This study provides a better understanding on the neurobiological mechanisms that may underlie risk of addiction development in carriers of the A118G SNP in <i>OPRM1</i>. <b>SIGNIFICANCE STATEMENT</b> The pandemic of opioid drug abuse is associated with many socioeconomic burdens. The primary brain target of opioid drugs is the μ-opioid receptor (MOR), encoded by the <i>OPRM1</i> gene, which is highly polymorphic in humans. Using a mouse model of the human <i>OPRM1</i> A118G single nucleotide polymorphism (SNP) (A112G in mice), we demonstrated that MOR and GABA<sub>B</sub> signaling coordinate in regulating mesolimbic dopamine neuronal firing via presynaptic regulation. The A118G SNP affects MOR-mediated suppression of GABA and glutamate release, showing weaker efficacy of synaptic regulation by MORs. These results may shed light on whether MOR SNPs need to be considered for devising effective therapeutic interventions.
43
Whole-Brain Mapping of Direct Inputs to Midbrain Dopamine Neurons
Mitsuko Watabe‐Uchida, Lisa Zhu, Sachie K. Ogawa et al. · Neuron · 2012 · 1.3K citations · Full text
Circuit Architecture of VTA Dopamine Neurons Revealed by Systematic Input-Output Mapping
Kevin T. Beier, Elizabeth E. Steinberg, Katherine E. DeLoach et al. · Cell · 2015 · 1.1K citations · Full text
Cherie E. Bond, K. Steven LaForge, Mingting Tian et al. · Proceedings of the National Academy of Sciences · 1998 · 1.1K citations